363
Participants
Start Date
January 8, 2018
Primary Completion Date
May 31, 2022
Study Completion Date
August 11, 2022
Isosorbide Mononitrate XL (ISMN)
Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
Cilostazol
Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models.
ISMN XL and Cilostazol
Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models. Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
Neither ISMN nor cilostazol
Neither isosorbide mononitrate nor Cilostazol administered for the entire duration of the study.
Royal Infirmary, Edinburgh
British Heart Foundation
OTHER
University of Nottingham
OTHER
University of Edinburgh
OTHER